Karyopharm Announces $30 Million Private Placement with RA Capital

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) entered a private placement with RA Capital expected to raise approximately $30 million in gross proceeds, with an additional $44 million/b) if accompanying warrants are exercised in full. The financing includes 1,030,354 common shares, 3,391,164 pre-funded warrants, and warrants for 4,421,518 shares.The offering was priced at-the-market under Nasdaq rules and is expected to close on or about March 26, 2026. Net proceeds plus existing liquidity are expected to fund operations into late Q3 2026. Proceeds are for general corporate purposes and planned clinical trial activities.

Positive

• Gross proceeds of $30 million before fees
• Potential additional $44 million if warrants exercised
• Net proceeds plus liquidity fund operations into late Q3 2026

Negative

• Issuance of 1,030,354 common shares and 4,421,518 warrants
• Granting of 3,391,164 pre-funded warrants immediately exercisable

News Market Reaction – KPTI

-18.32% 21.3x vol

37 alerts

-18.32% News Effect

+40.5% Peak Tracked

-19.0% Trough Tracked

-$27M Valuation Impact

$122.17M Market Cap

21.3x Rel. Volume

On the day this news was published, KPTI declined 18.32%, reflecting a significant negative market reaction. Argus tracked a peak move of +40.5% during that session. Argus tracked a trough of -19.0% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $27M from the company's valuation, bringing the market cap to $122.17M at that time. Trading volume was exceptionally heavy at 21.3x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Private placement gross proceeds: $30 million Additional warrant proceeds: $44 million Common shares sold: 1,030,354 shares +5 more

8 metrics

Private placement gross proceeds $30 million Expected gross proceeds before fees from RA Capital private placement

Additional warrant proceeds $44 million Potential gross proceeds if accompanying warrants are fully exercised

Common shares sold 1,030,354 shares Common stock issued at $6.785 per share in private placement

Common share price $6.785 per share Purchase price for common stock in the private placement

Pre-funded warrants 3,391,164 warrants Pre-funded warrants sold at $6.7849 each

Pre-funded warrant price $6.7849 per warrant Purchase price for each pre-funded warrant

Accompanying warrants 4,421,518 shares Shares underlying accompanying warrants exercisable at $10.00

Warrant exercise price $10.00 per share Exercise price for accompanying warrants

Market Reality Check

Price: $5.48 Vol: Volume 957,370 is 1.32x t...

normal vol

$5.48 Last Close

Volume Volume 957,370 is 1.32x the 20-day average, indicating elevated trading activity ahead of this financing. normal

Technical Shares at $6.66 are trading above the 200-day MA at $6.22, but remain 39.4% below the 52-week high.

Peers on Argus

KPTI was down 12.71% while peers like CUE (-1.83%), PYPD (-2.12%) and CAMP (-6.3...

KPTI was down 12.71% while peers like CUE (-1.83%), PYPD (-2.12%) and CAMP (-6.39%) also declined, but MAIA rose 2.05%. Mixed peer moves and a large KPTI-specific drop point to a company-specific reaction to the private placement.

Historical Context

5 past events · Latest: Mar 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Inducement grants	Neutral	-4.8%	Routine Nasdaq Rule 5635(c)(4) inducement RSU grants to new employees.
Feb 12	Earnings results	Neutral	+21.3%	Reported 2025 revenue, reiterated 2026 guidance, outlined key Phase 3 catalysts.
Feb 05	Earnings date	Neutral	-3.3%	Announced timing and call details for Q4 and full‑year 2025 results.
Feb 02	Inducement grants	Neutral	+3.8%	Additional RSU inducement grants under 2022 Inducement Stock Incentive Plan.
Jan 12	Clinical/financial update	Neutral	-5.6%	Preliminary 2025 revenue, Phase 3 timelines, and liquidity guidance into Q2 2026.

Pattern Detected

Recent news items have generally been routine (inducement grants, scheduling, preliminary results), with modest price moves except for a stronger reaction to earnings.

Recent Company History

Over recent months, Karyopharm reported preliminary and full‑year 2025 revenue around $145M–$146.1M, with U.S. XPOVIO revenue near $115M, and reiterated 2026 revenue guidance. The company highlighted key Phase 3 catalysts (SENTRY in March 2026 and XPORT‑EC‑042 in mid‑2026) and disclosed year‑end cash of $64.1M with runway into the second quarter of 2026. Against this backdrop, the new private placement extends liquidity but adds equity overhang relative to prior updates.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-11-03

An effective S-3 resale registration filed on 2025-11-03 covers up to 2,805,688 shares offered by selling stockholders, from which the company does not receive direct proceeds except upon warrant exercise. This sits alongside the new private placement as an additional source of potential secondary share supply.

Market Pulse Summary

The stock dropped -18.3% in the session following this news. A negative reaction despite strengthene...

Analysis

The stock dropped -18.3% in the session following this news. A negative reaction despite strengthened liquidity fits concerns about dilution and balance‑sheet risk. The company recently disclosed substantial doubt about its ability to continue as a going concern and tied debt relief to raising at least $25.0M of equity. This $30M private placement plus additional warrant overhang and an existing resale registration could weigh on sentiment even as it funds operations into late Q3 2026.

Key Terms

private placement, pre-funded warrants, warrants, Nasdaq rules

4 terms

private placement financial

"entered into a securities purchase agreement with RA Capital Management for a private placement"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

pre-funded warrants financial

"3,391,164 pre-funded warrants at a price of $6.7849 per pre-funded warrant"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

warrants financial

"accompanying warrants to purchase 4,421,518 shares of common stock with an exercise price of $10.00 per share"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Nasdaq rules regulatory

"The private placement was priced at-the-market under Nasdaq rules."

Nasdaq rules are a set of guidelines and requirements that companies must follow to be listed and remain on the Nasdaq stock exchange. These rules help ensure companies are transparent, financially healthy, and operate fairly, which is important for investors to trust the market and make informed decisions. Think of them as the standards that keep the marketplace honest and organized.

AI-generated analysis. Not financial advice.

NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full.

In the private placement, the Company agreed to sell 1,030,354 shares of common stock at a price of $6.785 per share, 3,391,164 pre-funded warrants at a price of $6.7849 per pre-funded warrant, and accompanying warrants to purchase 4,421,518 shares of common stock with an exercise price of $10.00 per share. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable and will not expire. The accompanying warrants will be immediately exercisable and will expire 30 days following the public announcement by the Company of topline results from the Phase 3 XPORT-EC-042 clinical trial of selinexor in patients with endometrial cancer.

The private placement is expected to close on or about March 26, 2026, subject to the satisfaction of customary closing conditions. The private placement was priced at-the-market under Nasdaq rules.  The Company expects that the net proceeds of the private placement, together with its existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will enable it to fund its current operating plans into late Q3 2026.

The Company intends to use the proceeds from the private placement for general corporate purposes, including to support the Company's ongoing and planned clinical trial activities.

Jefferies and Piper Sandler acted as placement agents for the private placement.

The offer and sale of the shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) are not being registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws. The shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock, pre-funded warrants, warrants, or any other securities, nor shall there be any offer, solicitation or sale of shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected closing date of the private placement, the Company's expected cash runway following closing of the private placement, and the Company's expected use of proceeds from the private placement.  Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical trials; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; substantial doubt exists regarding Karyopharm's ability to continue as a going concern; development or regulatory approval of drug candidates by Karyopharm's competitors for products or product candidates in which Karyopharm is currently commercializing or developing; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (SEC) on February 13, 2026, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-announces-30-million-private-placement-with-ra-capital-302723247.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

How much will KPTI raise in the March 24, 2026 private placement with RA Capital?

Karyopharm expects to raise approximately $30 million in gross proceeds, before fees. According to the company, an additional approximately $44 million could be raised if the accompanying warrants are exercised in full.

What securities did KPTI sell in the private placement announced March 24, 2026?

Karyopharm sold common stock, pre-funded warrants, and accompanying warrants in the placement. According to the company, the deal includes 1,030,354 common shares, 3,391,164 pre-funded warrants, and warrants for 4,421,518 shares.

When does the KPTI private placement with RA Capital expect to close and what is the timing?

The private placement is expected to close on or about March 26, 2026, subject to customary conditions. According to the company, closing timing depends on satisfying those customary closing conditions.

How long will the proceeds from the KPTI March 24, 2026 financing fund operations?

Proceeds plus existing liquidity are expected to fund operations into late Q3 2026. According to the company, that estimate includes cash, cash equivalents, investments, and expected product and license revenues.

What are the exercise terms and expirations for the warrants in KPTI's financing?

Accompanying warrants have a $10.00 exercise price and expire 30 days after topline Phase 3 results are announced. According to the company, pre-funded warrants are exercisable immediately at $0.0001 and do not expire.